126 related articles for article (PubMed ID: 38677763)
61. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways.
Acharya B; Chaijaroenkul W; Na-Bangchang K
J Pharm Pharmacol; 2021 Aug; 73(9):1191-1200. PubMed ID: 33885818
[TBL] [Abstract][Full Text] [Related]
62. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
63. Mitochondriome and cholangiocellular carcinoma.
Bahitham W; Liao X; Peng F; Bamforth F; Chan A; Mason A; Stone B; Stothard P; Sergi C
PLoS One; 2014; 9(8):e104694. PubMed ID: 25137133
[TBL] [Abstract][Full Text] [Related]
64. LncRNA HOTAIR suppresses cell apoptosis, autophagy and induces cell proliferation in cholangiocarcinoma by modulating the miR-204-5p/HMGB1 axis.
Lu M; Qin X; Zhou Y; Li G; Liu Z; Yue H; Geng X
Biomed Pharmacother; 2020 Oct; 130():110566. PubMed ID: 32755793
[TBL] [Abstract][Full Text] [Related]
65. Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release.
Kong C; Li Y; Liu Z; Ye J; Wang Z; Zhang L; Kong W; Liu H; Liu C; Pang H; Hu Z; Gao J; Qian F
ACS Nano; 2019 Apr; 13(4):4049-4063. PubMed ID: 30912923
[TBL] [Abstract][Full Text] [Related]
66. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
[No Abstract] [Full Text] [Related]
67. CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.
Kim J; Hwan Kim S
PLoS One; 2013; 8(9):e74342. PubMed ID: 24023938
[TBL] [Abstract][Full Text] [Related]
68. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
[TBL] [Abstract][Full Text] [Related]
69. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
70. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma.
Raggi C; Taddei ML; Sacco E; Navari N; Correnti M; Piombanti B; Pastore M; Campani C; Pranzini E; Iorio J; Lori G; Lottini T; Peano C; Cibella J; Lewinska M; Andersen JB; di Tommaso L; Viganò L; Di Maira G; Madiai S; Ramazzotti M; Orlandi I; Arcangeli A; Chiarugi P; Marra F
J Hepatol; 2021 Jun; 74(6):1373-1385. PubMed ID: 33484774
[TBL] [Abstract][Full Text] [Related]
71. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.
Seguin L
Subcell Biochem; 2022; 98():189-204. PubMed ID: 35378709
[TBL] [Abstract][Full Text] [Related]
72. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells.
Jinawath A; Akiyama Y; Sripa B; Yuasa Y
J Cancer Res Clin Oncol; 2007 Apr; 133(4):271-8. PubMed ID: 17294242
[TBL] [Abstract][Full Text] [Related]
73. CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression.
Yang B; Zhang J; Wang J; Fan W; Barbier-Torres L; Yang X; Justo MAR; Liu T; Chen Y; Steggerda J; Ramani K; Lu SC; Yang H
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37347224
[TBL] [Abstract][Full Text] [Related]
74. The endocytic pathway taken by cationic substances requires Rab14 but not Rab5 and Rab7.
Trofimenko E; Homma Y; Fukuda M; Widmann C
Cell Rep; 2021 Nov; 37(5):109945. PubMed ID: 34731620
[TBL] [Abstract][Full Text] [Related]
75. Protein kinase CK2 impact on intracellular calcium homeostasis in prostate cancer.
Afzal M; Kren BT; Naveed AK; Trembley JH; Ahmed K
Mol Cell Biochem; 2020 Jul; 470(1-2):131-143. PubMed ID: 32436081
[TBL] [Abstract][Full Text] [Related]
76. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
Kabashima A; Hirsova P; Bronk SF; Hernandez MC; Truty MJ; Ilyas SI; Kaufmann SH; Gores GJ
J Hepatol; 2018 Jun; 68(6):1228-1238. PubMed ID: 29408314
[TBL] [Abstract][Full Text] [Related]
77. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
78. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
79. CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.
Dana P; Saisomboon S; Kariya R; Okada S; Obchoei S; Sawanyawisuth K; Wongkham C; Pairojkul C; Wongkham S; Vaeteewoottacharn K
Cell Oncol (Dordr); 2020 Apr; 43(2):211-222. PubMed ID: 31729681
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
